Services
Biologic Therapeutics Development
Antibody & Protein Discovery
Target Discovery & Validation
Antibody Discovery
Antibody & Protein Production
Preclinical Testing
Structure & Biochemical Characterization
Preclinical Testing Bioassays & Immunoassays
Efficacy Models
Antibody & Protein Pharmacology
Antibody & Protein Toxicology
In Vitro
ADME
CDMO
Cell Line Development
Cell Banking
Analytical & Bioassay Quality Control
Pharmaceutical Stability Analysis
Lot Release Testing
cGMP Manufacturing
IND Regulatory
Co-Development Program by Targets
Next-IO™ T Cell related Therapeutics
Next-IO™ Anti-FGL1 Monoclonal Antibody Program
Next-IO™ Anti-FGL2 Monoclonal Antibody Program
Next-IO™ Anti-Siglec-15 Monoclonal Antibody Program
Next-IO™ Anti-TIM3 Monoclonal Antibody Program
Next-IO™ Anti-4-1BB Monoclonal Antibody Program
Next-IO™ Anti-CD19 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD27 Monoclonal Antibody Program
Next-IO™ Anti-CD40L Monoclonal Antibody Program
Next-IO™ Anti-GITR Monoclonal Antibody Program
Next-IO™ Anti-ICOS Monoclonal Antibody Program
Next-IO™ Anti-TMIGD2 Monoclonal Antibody Program
Next-IO™ Anti-HVEM/TNFRSF14 Monoclonal Antibody Program
Next-IO™ Anti-VISTA Monoclonal Antibody Program
Next-IO™ Anti-PD1 × TIM3 Bispecific Antibody Program
Next-IO™ Anti-TIGIT Monoclonal Antibody Program
Next-IO™ Anti-BTLA Monoclonal Antibody Program
Next-IO™ Anti-CD160 Monoclonal Antibody Program
Next-IO™ Anti-CTLA-4 × CD40 Combination Antibody Program
Next-IO™ Anti-PD-L1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-ROR1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD20 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD226 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD96 Therapeutic Monoclonal Antibody Program
Next-IO™ ICOS × PD-1 Therapeutic Bispecific Antibody Program
Next-IO™ APC related Therapeutics
Next-IO™ Anti-B7-H4 × CD3 Bispecific Antibody Program
Next-IO™ Anti-B7-H3 × CD3 Bispecific Antibody Program
Next-IO™ Anti-4-1BBL Therapeutic Fusion Protein Program
Next-IO™ Anti-CD40 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD70 Therapeutic Fusion Protein Program
Next-IO™ Anti-CD70 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-ICOSL Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-HHLA2 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Galectin-9 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD112 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD155 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-OX40L Therapeutic Fusion Protein Program
Next-IO™ Anti-GITRL Therapeutic Fusion Protein Program
Next-IO™ NK Cell related Therapeutics
Next-IO™ Fusion Proteins of NKG2D Program
Next-IO™ Anti-sMIC Monoclonal Antibody Program
Next-IO™ Anti-CD48 Monoclonal Antibody Program
Next-IO™ Anti-2B4 Monoclonal Antibody Program
Next-IO™ Anti-HLA-G Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL4 Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL1-3 Monoclonal Antibody Program
Next-IO™ Anti-CD94/NKG2A Monoclonal Antibody Program
Next-IO™ Anti-PVR Monoclonal Antibody Program
Next-IO™ Anti-CD96 Monoclonal Antibody Program
Next-IO™ Anti-CD16 IgG Program
Next-IO™ Anti-LILRB1 Monoclonal Antibody Program
Next-IO™ Anti-KLRG1 Monoclonal Antibody Program
Next-IO™ Anti-Cadherin Monoclonal Antibody Program
Next-IO™ Anti-LLT1 Monoclonal Antibody Program
Next-IO™ Anti-NKRP1A Monoclonal Antibody Program
Next-IO™ Targeting Sialic Acid Program
Next-IO™ Anti-Nectin-2 Monoclonal Antibody Program
Next-IO™ Tumor Associated Antigens
Next-IO™ Anti-CD73 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPVI Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Phosphatidylserine Monoclonal Antibody Program
Next-IO™ Anti-CD47 Therapeutic Monoclonal Antibody Program
Next-IO™ CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-Ang2 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-BCMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD123 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × PD-L1 Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ CD47 × CD19 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × MSLN Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × EGFR Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ TGF-β × PD-L1 Bi-Functional Therapeutic Fusion Protein Program
Next-IO™ Anti-GPC3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPA33 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-GPRC5D × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPC3 Therapeutic CAR-T Cell Program
Next-IO™ Anti-GPC3 Therapeutic CAR-NK Cell Program
Next-IO™ Anti-MUC16 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CDH3 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-PSMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-SSTR2 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-MSLN Therapeutic Fusion Protein Program
Next-IO™ Anti-MSLN × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × CD20 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific DART Program
Next-IO™ Anti-CD24 Monoclonal Antibody Program
Next-IO™ PD-L1 × TIM-3 Therapeutic Bispecific Antibody Program
Next-IO™ PD-1 × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ PSCA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ 4-1BB × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ A2AR Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Galectin-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 Therapeutic Vaccine Program
Next-IO™ Anti-LAG-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-YTHDF1 Therapeutic Monoclonal Antibody Program
Next-IO™ c-MET × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ CD22 × CD19 Therapeutic CAR-T Program
Next-IO™ CD22 Therapeutic CAR-T Program
Next-IO™ CTLA-4 × OX40 Therapeutic Bispecific Antibody Program
Next-IO™ GITR × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ HER2 × HER3 Therapeutic Bispecific Antibody Program
Next-IO™ HER3 Therapeutic Monoclonal Antibody Program
Next-IO™ LAG-3 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ LAG-3 × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ LGR5 Therapeutic Monoclonal Antibody Program
Next-IO™ MHC I:LILRB2 Axis Therapeutic Monoclonal Antibody Program
Next-IO™ PAUF Therapeutic Monoclonal Antibody Program
Next-IO™ Chemokines & Chemokine Receptors-Related Therapeutics
Next-IO™ Anti-CCL2/CCR2 Axis Targeted Therapeutic Antibody Program
COVID-19 Recovered Patient-Derived Anti-SARS-CoV-2 Therapeutic Antibody Development
Next-IO™ Alzheimer's Disease Therapeutics
Next-IO™ Macrophages-related Therapeutics
Products
Oncology Cell Lines
Cancer Cell Lines
Reporter Cell Lines
Luciferase Cell Lines
EGFP Cell Lines
Dual Labeled Cell Lines
Gene Editing Cell Lines
KO Cell Lines
Knockin Cell Lines
Knockdown Cell Lines
Primary Cells
Stem Cells
Drug Resistant Cells
OncoImmune Cells
Oncology Kits
Consumables
Tumor Marker Kits
Oncology Assay Tools
Metabolomics Analysis Tools
Animal Models
Synthetic Gene Circuit Cells
Cell Transport Capsule Kits
ADME
Absorption
Distribution
Metabolism
Excretion
Collaborations
Company
About Us
Contact Us
Careers
Online Inquiry
Webinars
Events
Service
Product
Search
Home
Products
Oncology Kits
Human CTLA4 ELISA Kit, Lot 21AO-625 [Cancer Immune Checkpoint Assay Kit]
Inquiry
Datasheet
CAT#:
IOK-05-P536
Product Type:
ELISA Kit
Target:
CTLA4
Overview
Short Description
The kit is designed for
in vitro
quantitative measurement of Human CTLA4 in Plasma, Serum, Tissue Samples.
Description
Quantitative measurement of CTLA4 in human serum, plasma, cell culture supernatant and other biological fluids.
Applications
ELISA
Application Notes
Quantitative measurement of CTLA4 in human serum, plasma, cell culture supernatant, and other biological fluid.
Comment
Further details regarding sample type: Human serum, plasma, tissue homogenates and other biological fluids.
Target
CTLA4
Reactivity
Human
Detection Method
Colorimetric
Method Type
Sandwich ELISA
Analytical Method
Quantitative
Sample Type
Plasma, Serum, Tissue Samples
Specification
Components
Micro ELISA Plate
Lyophilized Standard
Sample / Standard dilution buffer
Biotin- detection antibody (Concentrated)
Antibody dilution buffer
HRP-Streptavidin Conjugate (SABC)
SABC dilution buffer
TMB substrate
Stop Solution
Wash buffer (25X)
Plate sealers
Plate
Pre-coated
Storage
4 °C
Expiry Date
6 months
Restrictions
For Research Use only
Target Details
Alternative Name
Cytotoxic T-Lymphocyte Associated Antigen 4
Synonyms
CTLA-4; CTLA4; CD152; Cd152; Ctla-4; Ly-56; CD; CELIAC3; GRD4; GSE; IDDM12; sCTLA4; cytotoxic T-lymphocyte associated protein 4; cytotoxic T-lymphocyte-associated protein 4; CTLA4; Ctla4
Background
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
Gene ID
1493
UniProt
P16410
Pathways
Cancer Immune Checkpoints
Related Products
PharmaOnco™ Mouse CD25+ Treg Cell Isolation Kit
(CAT#: ITS-0622-YT426)
PharmaOnco™ AAV-DJ/8 Assay Kit
(CAT#: ITS-0622-HM66)
SIAH1 Histology Assay Kit
(CAT#: ITS-1122-ZP3496)
CASK Histology Assay Kit
(CAT#: ITS-1122-ZP568)
GANAB / Alpha Glucosidase II Histology Assay Kit
(CAT#: ITS-1122-ZP1485)
PharmaOnco™ African Swine Fever PCR Kit
(CAT#: ITS-0622-HM93)
PharmaOnco™ Mouse Naïve CD8+ T Cell Isolation Kit
(CAT#: ITS-0622-YT419)
ARHGEF11 Histology Assay Kit
(CAT#: ITS-1122-ZP298)
For Research Use Only | Not For Clinical Use
Online Inquiry
Send